Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study

The bone evaluation study (BEST): patient care and persistence to treatment of osteoporosis in Germany

(2013) Peyman Hadji et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013

(2013) J. Compston et al.   MATURITAS

The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis

(2013) P. Hadji et al.   OSTEOPOROSIS INTERNATIONAL

Treatment Persistence in Swedish Women Initiating Denosumab Treatment for Postmenopausal Osteoporosis

(2013) L. Karlsson et al.   VALUE IN HEALTH

Osteoporosis in the European Union: medical management, epidemiology and economic burden

(2013) E. Hernlund et al.   Archives of Osteoporosis

Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis

(2012) N. Freemantle et al.   OSTEOPOROSIS INTERNATIONAL

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

(2012) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

Quality of life and health status with zoledronic acid and generic alendronate—a secondary analysis of the Rapid Onset and Sustained Efficacy (ROSE) study in postmenopausal women with low bone mass

(2011) P. Hadji et al.   OSTEOPOROSIS INTERNATIONAL

GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates

(2011) P. Hadji et al.   OSTEOPOROSIS INTERNATIONAL

Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women

(2011) N. Freemantle et al.   OSTEOPOROSIS INTERNATIONAL

Efficacy and Safety of Monthly 150 mg Oral Ibandronate in Women with Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials

(2011) Young Ho Lee et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density

(2010) H.K. Genant et al.   BONE

Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009

(2010) S. Lee et al.   OSTEOPOROSIS INTERNATIONAL

Adherence and profile of non-persistence in patients treated for osteoporosis—a large-scale, long-term retrospective study in The Netherlands

(2010) J. C. Netelenbos et al.   OSTEOPOROSIS INTERNATIONAL

Impact of Osteoporosis Treatment Adherence on Fracture Rates in North America and Europe

(2009) Ethel S. Siris et al.   AMERICAN JOURNAL OF MEDICINE

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy

(2009) David L Kendler et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis

(2009) I. Imaz et al.   OSTEOPOROSIS INTERNATIONAL

Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II)

(2008) Peyman Hadji et al.   JOINT BONE SPINE

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*

(2008) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women

(2008) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Predictive Validity of a Medication Adherence Measure in an Outpatient Setting

(2008) Donald E. Morisky et al.   Journal of Clinical Hypertension

Medication Compliance and Persistence: Terminology and Definitions

(2007) Joyce A. Cramer et al.   VALUE IN HEALTH